

Sepsis - Pipeline Insight, 2021

<https://marketpublishers.com/r/S05BB269F768EN.html>

Date: May 2021

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: S05BB269F768EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Sepsis - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Sepsis Understanding

Sepsis: Overview

Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicaemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Sepsis develops when the immune system releases the chemicals in the bloodstream to fight an infection cause inflammation throughout the entire body instead. Sepsis is more common in People with chronic medical conditions, such as diabetes, lung disease, cancer, and kidney disease, People with weakened immune systems, babies under 1 year of age, elderly people especially if they have other health problems.

'Sepsis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.

Sepsis Emerging Drugs Chapters

This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sepsis Emerging Drugs

Thymosin alpha 1: SciClone Pharmaceuticals

Thymosin alpha 1, generically referred to as thymalfasin, is a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement. SciClone developed and launched Thymosin alpha 1, under the trade name Zadaxin, for the treatment of hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections. The drug is also being developed for the treatment of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS, sepsis and malignant melanoma. The drug is in phase 3 of development stage for the treatment of sepsis.

VBI-S: Vivacelle Bio

VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is likely to be effective in septic shock due to COVID or bacteria even when current therapy has failed. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.

Further product details are provided in the report

Sepsis: Therapeutic Assessment

This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sepsis

There are approx. 35+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. phase III include, SciClone Pharmaceuticals.

Phases

DelveInsight's report covers around 35+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Recombinant proteins

Small molecule

Cell therapy

Liposome

Vaccines

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sepsis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Sepsis Report Insights

- Sepsis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Sepsis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Sepsis drugs?

How many Sepsis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Sepsis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

SciClone Pharmaceuticals

Vivacelle Bio

InflaRx

Grifols

Cidara Therapeutics

AM-Pharma

Asahi Kasei Pharma

Sanofi

Shionogi

Paion

Inoterm

InflaRx GmbH

Enlivex Therapeutics

Biomedizinische Forschungsgesellschaft

Abionyx

Adrenomed

TiGenix

Tianjin Chasesun Pharmaceutical

Suzhou Yabao Pharmaceutical

Shaperon

Genentech

Noxopharm

Vascular Biosciences

Karyopharm Therapeutics

Arch Biopartners

Tetra Bio-Pharma

Cellics Therapeutics

Scioto Biosciences

Agile Biotics

Key Products

Thymosin alpha 1

VBI-S

Vilobelimab

Albutein

Rezafungin

Recombinant human alkaline phosphatase

ART-123

Alirocumab

Cefiderocol

Remimazolam

Nangibotide

CaCP29

Allocetra-OTS

rTSST-1v

CER-001

Adrecizumab

Cx 611

Kukoamine B

SY-005

HY209

DSTA 4637S

NOX66

NuSepin

CAR Adjuvant

Selinexor

Metablok

ARDS-003

Lipocurc

CTI-111

SB-121

ABX-605

Contents

Introduction

Executive Summary

Sepsis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Sepsis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Sepsis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Sepsis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Thymosin alpha 1: SciClone Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

VBI-S: Vivacelle Bio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

SY 005: Suzhou Yabao

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

- Comparative Analysis

CTI 105: Cellics Therapeutics

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Sepsis Key Companies

Sepsis Key Products

Sepsis- Unmet Needs

Sepsis- Market Drivers and Barriers

Sepsis- Future Perspectives and Conclusion

Sepsis Analyst Views

Sepsis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Sepsis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Sepsis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Sepsis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/S05BB269F768EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S05BB269F768EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970